William L. Mulert

President & CEO, Co-founder

Mr. Mulert is a seasoned executive with over thirty years experience in the high tech industry. Prior to starting TCT, he was President and CEO of Clientele Software, a firm specializing in Customer Relationship Management (CRM) software for small and medium sized companies. He led the company from its start-up phase up to its acquisition by a public company. Prior to that he was a sales and marketing executive at several high-tech start-ups after starting his career in sales at Hewlett Packard and IBM. He has a BS in Electrical Engineering from Iowa State University. email: bmulert@targetedcancer.com

William L. Mulert

Daruka Mahadevan MD, Ph.D.

Chief Scientific Officer, Co-founder

Dr. Mahadevan is the inventor of our products, and a pioneer in the field of drug design and the study of pancreatic cancer. He is a Professor of Medicine at the Univ. of Arizona in Tucson. He is also, Director, New Therapeutics Program, Co-Chair, Therapeutic Development Program, Endowed Chair, Margaret E. and Fenton L. Maynard Excellence in Breast Cancer Research, University of Arizona Cancer Center. Previously, he was a Professor of Medicine at the University of Tennessee Health Science Center, College of Medicine, Division of Hematology Oncology in Memphis and Director of the Phase I Program and Associate Director of Research at The West Clinic in Memphis. Dr. Mahadevan’s major area of clinical interest is in the treatment and management of patients with Pancreatic cancer, Breast cancer, Gastrointestinal Stromal Tumors (GIST), Myelodysplastic Syndromes (MDS) and non-Hodgkin’s lymphoma (NHL). He is one of very few physician-scientists in the U.S. with a Ph.D. in protein crystallography, molecular modeling and drug design who is also board certified in medical oncology and practicing.

Daruka Mahadevan MD, Ph.D.

Stephan F. Toutain

Board Member

Mr. Toutain has more than 20 years of healthcare experience in biopharmaceuticals and medical devices. He has launched many biopharmaceutical products in the area of orphan diseases, oncology, hematology and cardiovascular disease. Mr. Toutain was GM of Eastern Europe, Switzerland and CIS Area at Alexion Pharmaceuticals. Previously he held several executive and senior management positions in Marketing, Commercial Operations at Alexion and at Celgene for the US and global markets. Prior to that, Mr. Toutain worked for J&J in Marketing and New Business Development. He also brings more than 8 years of start-up launch, sales leadership and early clinical development. Mr. Toutain has a MBA from the University of North Carolina-Chapel Hill, and a MS from the University of Nancy, France.

Stephan F. Toutain

Daniel D. Von Hoff, M.D., F.A.C.P.

Scientific Advisor

Dr. Von Hoff is Physician in Chief and Director of Translational Research at Translational Genomics Research Institute. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute. He is also a Clinical Professor of Medicine, University of Arizona and a recognized expert on pancreatic cancer as well as lead investigator for Abraxane. —Moffitt Cancer Center (A. List, MD; J. Lancet, MD; G. Reuther, MD).

Van Hoff

Gregory J. Decker, JD

Technical Advisor

Mr. Decker has more than twenty+ years of healthcare experience in biopharmaceuticals and technology specializing in the commercialization and growth phases of company development. Mr. Decker has an BSCS from new Jersey Institute of Technology and a Juris Doctorate from Vermont Law School.

Gregory Decker